参考文献/References:
[1] 刘迎龙,苏俊武. 建国70年来我国先天性心脏病诊治回顾与进展[J]. 中国医药,2019,14(9):1281-1284.
[2] Typpo KV,Larmonier CB,Deschenes J,et al. Clinical characteristics associated with postoperative intestinal epithelial barrier dysfunction in children with congenital heart disease[J]. Pediatr Crit Care Med,2015,16(1):37-44.
[3] Salomon J,Ericsson A,Price A,et al. Dysbiosis and intestinal barrier dysfunction in pediatric congenital heart disease is exacerbated following cardiopulmonary bypass[J]. JACC Basic Transl Sci,2021,6(4):311-327.
[4] Ding W,Liu J,Zhou X,et al. Clinical multi-omics study on the gut microbiota in critically ill patients after cardiovascular surgery combined with cardiopulmonary bypass with or without sepsis (MUL-GM-CSCPB Study):a prospective study protocol[J]. Front Med (Lausanne),2020,7:269.
[5] Hirata Y. Cardiopulmonary bypass for pediatric cardiac surgery[J]. Gen Thorac Cardiovasc Surg,2018,66(2):65-70.
[6] Zhang X,Zhang W,Lou H,et al. Risk factors for prolonged intensive care unit stays in patients after cardiac surgery with cardiopulmonary bypass:a retrospective observational study[J]. Int J Nurs Sci,2021,8(4):388-393.
[7] Kalder J,Ajah D,Keschenau P,et al. Microcirculatory perfusion shift in the gut wall layers induced by extracorporeal circulation[J]. J Vasc Surg,2015,61(2):497-503.
[8] Sakamoto T,Fujiogi M,Matsui H,et al. Clinical features and outcomes of nonocclusive mesenteric ischemia after cardiac surgery:a retrospective cohort study[J]. Heart Vessels,2020,35(5):630-636.
[9] Adamik B,Kübler A,Gozdzik A,et al. Prolonged cardiopulmonary bypass is a risk factor for intestinal ischaemic damage and endotoxaemia[J]. Heart Lung Circ,2017,26(7):717-723.
[10] Serek P,Oleksy-Wawrzyniak M. The effect of bacterial infections,probiotics and zonulin on intestinal barrier integrity[J]. Int J Mol Sci,2021,22(21):11359.
[11] Shi N,Li N,Duan X,et al. Interaction between the gut microbiome and mucosal immune system[J]. Mil Med Res,2017,4:14.
[12] Chelakkot C,Ghim J,Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications[J]. Exp Mol Med,2018,50(8):1-9.
[13] 金鹏锋,陈琳,胡耀仁,等. 脓毒症的肠道发病机制研究进展[J]. 中华医院感染学杂志,2018,28(10):1441-1445.
[14] Zhao Q,Maynard CL. Mucus,commensals,and the immune system[J]. Gut Microbes,2022,14(1):2041342.
[15] Gai X,Wang H,Li Y,et al. Fecal microbiota transplantation protects the intestinal mucosal barrier by reconstructing the gut microbiota in a murine model of sepsis[J]. Front Cell Infect Microbiol,2021,11:736204.
[16] 黄艳,梁小琴,张敏,等. 新生儿坏死性小肠结肠炎不良预后危险因素分析[J]. 中华新生儿科杂志,2018,33(5):368-371.
[17] Tsou AM,Goettel JA,Bao B,et al. Utilizing a reductionist model to study host-microbe interactions in intestinal inflammation[J]. Microbiome,2021,9(1):215.
[18] Tian Y,Shu R,Lei Y,et al. Somatostatin attenuates intestinal epithelial barrier injury during acute intestinal ischemia-reperfusion through Tollip/Myeloiddifferentiationfactor 88/Nuclear factor kappa-B signaling[J]. Bioengineered,2022,13(3):5005-5020.
[19] Jin C,Fu WL,Zhang D,et al. The protective role of IL-1Ra on intestinal ischemia reperfusion injury by anti-oxidative stress via Nrf2/HO-1 pathway in rat[J]. Biomed J,2019,42(1):36-45.
[20] Deng F,Zhao BC,Yang X,et al. The gut microbiota metabolite capsiate promotes Gpx4 expression by activating TRPV1 to inhibit intestinal ischemia reperfusion-induced ferroptosis[J]. Gut Microbes,2021,13(1):1-21.
[21] Camara-Lemarroy CR,Metz L,Meddings JB,et al. The intestinal barrier in multiple sclerosis:implications for pathophysiology and therapeutics[J]. Brain,2018,141(7):1900-1916.
[22] Li Y,Song Z,Kerr K A,et al. Chronic social stress in pigs impairs intestinal barrier and nutrient transporter function,and alters neuro-immune mediator and receptor expression[J]. PLoS One,2017,12(2):e0171617.
[23] Lock JY,Caboni M,Strandwitz P,et al. An in vitro intestinal model captures immunomodulatory properties of the microbiota in inflammation[J]. Gut Microbes,2022,14(1):2039002.
[24] Itoh H,Ichiba S,Ujike Y,et al. A prospective randomized trial comparing the clinical effectiveness and biocompatibility of heparin-coated circuits and PMEA-coated circuits in pediatric cardiopulmonary bypass[J]. Perfusion,2016,31(3):247-254.
[25] Fernández-Tomé S,Ortega Moreno L,Chaparro M,et al. Gut microbiota and dietary factors as modulators of the mucus layer in inflammatory bowel disease[J]. Int J Mol Sci,2021,22(19):10224.
[26] Hansson GC. Mucins and the Microbiome[J]. Annu Rev Biochem,2020,89:769-793.
[27] Paone P,Cani PD. Mucus barrier,mucins and gut microbiota:the expected slimy partners?[J]. Gut,2020,69(12):2232-2243.
[28] Tulstrup MV,Christensen EG,Carvalho V,et al. Antibiotic treatment affects intestinal permeability and gut microbial composition in Wistar rats dependent on antibiotic class[J]. PLoS One,2015,10(12):e0144854.
[29] 周文君,李元敏,杨小芳,等. 防治体外循环心脏直视术后肠道屏障功能损伤的研究进展[J]. 华中科技大学学报(医学版),2018,47(6):768-771.
[30] Hanedan M O,Yürük M A,Arslan A K,et al. Heparin-coated vs. non-coated cardiopulmonary bypass circuits:comparing immediate results with different target activated clotting time[J]. Braz J Cardiovasc Surg,2020,35(6):913-917.
[31] Lin H,Zhang X,Wang D,et al. Anwulignan ameliorates the intestinal ischemia/reperfusion[J]. J Pharmacol Exp Ther,2021,378(3):222-234.
[32] Ikeda M,Shimizu K,Ogura H,et al. Hydrogen-rich saline regulates intestinal barrier dysfunction,dysbiosis,and bacterial translocation in a murine model of sepsis[J]. Shock,2018,50(6):640-647.
[33] Mueller K,Kokotilo MS,Carter J M,et al. Creatine-loading preserves intestinal barrier function during organ preservation[J]. Cryobiology,2018,84:69-76.
[34] Reintam Blaser A,Acosta S,Arabi YM. A clinical approach to acute mesenteric ischemia[J]. Curr Opin Crit Care,2021,27(2):183-192.
[35] Shen J,Zhan Y,He Q,et al. Remifentanil promotes PDIA3 expression by activating p38MAPK to inhibit intestinal ischemia/reperfusion-induced oxidative and endoplasmic reticulum stress[J]. Front Cell Dev Biol,2022,10:818513.
[36] Li X,Yang C,Gulifeire T,et al. [Ulinastatin protects intestinal mucosal barrier by inhibiting the activation of intestinal NLRP3 inflammasomes in septic rats][J]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,2021,33(2):192-197.
[37] Zhang YN,Chang ZN,Liu ZM,et al. Dexmedetomidine alleviates gut-vascular barrier damage and distant hepatic injury following intestinal ischemia/reperfusion injury in mice[J]. Anesth Analg,2022,134(2):419-431.
[38] Dong J,Liang W,Wang T,et al. Saponins regulate intestinal inflammation in colon cancer and IBD[J]. Pharmacol Res,2019,144:66-72.
[39] Raheem A,Liang L,Zhang G,et al. Modulatory effects of probiotics during pathogenic infections with emphasis on immune regulation[J]. Front Immunol,2021,12:616713.
[40] Liu Q,Yu Z,Tian F,et al. Surface components and metabolites of probiotics for regulation of intestinal epithelial barrier[J]. Microb Cell Fact,2020,19(1):23.
[41] Hu J,Deng F,Zhao B,et al. Lactobacillus murinus alleviate intestinal ischemia/reperfusion injury through promoting the release of interleukin-10 from M2 macrophages via Toll-like receptor 2 signaling[J]. Microbiome,2022,10(1):38.
[42] 李元敏,崔芬芬,宋兵,等. 粪菌移植在体外循环术后肠道菌群失调患者中的应用[J]. 中国微生态学杂志,2019,31(2):202-205.
[43] Merenstein D,Fraser CM,Roberts RF,et al. Bifidobacterium animalis subsp. lactis BB-12 protects against antibiotic-induced functional and compositional changes in human fecal microbiome[J]. Nutrients,2021,13(8):2814.
[44] Szajewska H,Hojsak I. Health benefits of Lactobacillus rhamnosus GG and Bifidobacterium animalis subspecies lactis BB-12 in children[J]. Postgrad Med,2020,132(5):441-451.
[45] Guo Q,Goldenberg JZ,Humphrey C,et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea[J]. Cochrane Database Syst Rev,2019,4(4):CD004827.
相似文献/References:
[1]郭琳娟,洪葵.成人先天性心脏病心律失常的诊断和治疗进展[J].心血管病学进展,2015,(6):752.[doi:10.3969/j.issn.1004-3934.2015.06.024]
GUO Linjuan,HONG Kui.Advances in Diagnosis and Treatment of Adult Congenital Heart
Disease with Arrhythmia[J].Advances in Cardiovascular Diseases,2015,(6):752.[doi:10.3969/j.issn.1004-3934.2015.06.024]
[2]朱峰,陈铀.先天性心脏病相关肺动脉高压的治疗进展[J].心血管病学进展,2019,(6):894.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.014]
ZHU Feng,CHEN You.Congenital Heart Disease-related Pulmonary Arterial Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):894.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.014]
[3]黄金秋 路发文 赵永康 陈宇雨 史红蕊 王萍 杨菊仙.先天性心脏病患儿营养状况及其危险因素分析[J].心血管病学进展,2020,(12):1324.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.023]
HUANG Jinqiu,LU Fawen,ZHAO Yongkang,et al.Nutritional Status in Children with Congenital Heart Disease and the Influential Factors[J].Advances in Cardiovascular Diseases,2020,(6):1324.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.023]
[4]周玲梅 张文倩 张智伟.体-肺动脉分流术在建立先天性心脏病动物模型中的应用进展[J].心血管病学进展,2021,(7):628.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.013]
ZHOU Lingmei,ZHANG Wenqian,ZHANG Zhiwei.Application Progress of Systemic Pulmonary Arterial Shunt in Animal Model of Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2021,(6):628.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.013]
[5]林锡祥 杨菲菲 陈煦 何昆仑.人工智能赋能医学影像在先天性心脏病医学诊治中的研究进展[J].心血管病学进展,2022,(12):1063.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.002]
LIN Xixiang,YANG Feifei,CHEN Xu,et al.Artificial Intelligence Medical Imaging Technology in Medical Imaging of Congenital Heart Disease[J].Advances in Cardiovascular Diseases,2022,(6):1063.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.002]
[6]董捷 杜楚豪 董硕 刘顺 徐海涛 孙阳雪 邹孟轩 孙家树 李守军 杨克明 闫军.Uhl畸形诊断与治疗研究进展[J].心血管病学进展,2023,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.004]
DONG Jie DU Chuhao DONG ShuoLIU Shun,XU HaitaoSUN YangxueZOU MengxuanSUN JiashuLI Shoujun,YANG Keming,et al.Diagnosis and Treatment for Uhls Anomaly[J].Advances in Cardiovascular Diseases,2023,(6):686.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.004]
[7]陈颖慧 冯奕源 冯炜琦 吴逸卓 鲁亚南 于昱.血管发育异常的先天性心脏病患儿中Vav2基因突变的筛查和功能分析[J].心血管病学进展,2023,(8):757.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.019]
CHEN Yinghui,FENG Yiyuan,FENG Weiqi,et al.Identification and Functional Analysis of Vav2 Novel Variant in Congenital Heart Diseases with Vascular Malformation[J].Advances in Cardiovascular Diseases,2023,(6):757.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.019]
[8]李强强 顾虹.中国儿童肺动脉高压诊治现状[J].心血管病学进展,2024,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.003]
LI Qiangqiang,GU Hong.Current Status of Diagnosis and Treatment of Pulmonary Hypertension in Chinese Children[J].Advances in Cardiovascular Diseases,2024,(6):7.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.003]
[9]李思聪 罗勤 赵智慧 赵青 柳志红.房间隔缺损相关肺动脉高压机制及治疗进展[J].心血管病学进展,2024,(1):11.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.004]
LI Sicong,LUO Qin,ZHAO Zhihui,et al.Pathogenesis and Treatment of Pulmonary Hypertension Associated with Atrial Septal Defect[J].Advances in Cardiovascular Diseases,2024,(6):11.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.004]
[10]关璐茜 罗勤 胡海波.高原地区先天性心脏病相关性肺动脉高压的研究进展[J].心血管病学进展,2024,(1):15.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.005]
GUAN Luxi,LUO Qin,HU Haibo.Pulmonary Arterial Hypertension Associated with Congenital Heart Disease at High Altitude[J].Advances in Cardiovascular Diseases,2024,(6):15.[doi:10.16806/j.cnki.issn.1004-3934.2024.01.005]